Loading…
The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy
Methods: A multicenter, randomized, open‐label, observer‐blinded, parallel‐group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients 30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose...
Saved in:
| Published in: | Epilepsia (Copenhagen) 2007-09, Vol.48 (9), p.1716-1723 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3 |
| container_end_page | 1723 |
| container_issue | 9 |
| container_start_page | 1716 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 48 |
| creator | Kang, Hoon‐Chul Eun, Baik‐Lin Wu Lee, Chang Ku Moon, Han Kim, Joon‐Sik Wook Kim, Dong Soo Lee, Joon Young Chae, Kyu Ho Cha, Byung Sook Suh, Eun Chae Park, Jung Lim, Kyunghwa Hye Ha, Eun Ho Song, Dong Dong Kim, Heung |
| description | Methods: A multicenter, randomized, open‐label, observer‐blinded, parallel‐group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients 30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment.
Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM.
Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups. |
| doi_str_mv | 10.1111/j.1528-1167.2007.01160.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20530463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20530463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3</originalsourceid><addsrcrecordid>eNqNkc1u1DAQxy0EokvhFZAvcEuwnXWcPXCAaEsrFVGh5Wx57XHjVWIHO9t2eZW-LE53Ra_44tHMbz7_CGFKSprfp11JOWsKSmtRMkJESbJJyocXaPEv8BItCKFVseINOUNvUtqRTNaieo3OqOA1XXG2QI-bDvDaWtBTwsHjNtx6N7k7wBd7ryeXXcob_BU6dedCVD2-iWHbw5BpizdhdFENaoKcOIwqgsFTwK2K2-z9A6PzgFXC34MPUwdRjQdsQ8Rt53oTweN7N3W5uHe3Hv8MfW7lNF6ProcxHd6iV1b1Cd6d_nP062K9aS-L6x_frtov14VeioYUSy3qvA3YuiFCCcG2XDDT1HlHazRTlDeam0rb2gDT1BIqrGDW2EZVZEl1dY4-HuuOMfzeQ5rk4JKGPo8DYZ8kIzyDdZXB5gjqGFKKYOUY3aDiQVIiZ2HkTs73l_P95SyMfBJGPuTU96ce--0A5jnxpEQGPpwAlbTqbVReu_TMrQhfVkJk7vORu89HOvz3AHJ9czVb1V8BDatT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20530463</pqid></control><display><type>article</type><title>The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy</title><source>Wiley</source><creator>Kang, Hoon‐Chul ; Eun, Baik‐Lin ; Wu Lee, Chang ; Ku Moon, Han ; Kim, Joon‐Sik ; Wook Kim, Dong ; Soo Lee, Joon ; Young Chae, Kyu ; Ho Cha, Byung ; Sook Suh, Eun ; Chae Park, Jung ; Lim, Kyunghwa ; Hye Ha, Eun ; Ho Song, Dong ; Dong Kim, Heung</creator><creatorcontrib>Kang, Hoon‐Chul ; Eun, Baik‐Lin ; Wu Lee, Chang ; Ku Moon, Han ; Kim, Joon‐Sik ; Wook Kim, Dong ; Soo Lee, Joon ; Young Chae, Kyu ; Ho Cha, Byung ; Sook Suh, Eun ; Chae Park, Jung ; Lim, Kyunghwa ; Hye Ha, Eun ; Ho Song, Dong ; Dong Kim, Heung ; Korean Pediatric Topiramate Study Group</creatorcontrib><description>Methods: A multicenter, randomized, open‐label, observer‐blinded, parallel‐group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment.
Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM.
Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/j.1528-1167.2007.01160.x</identifier><identifier>PMID: 17561952</identifier><identifier>CODEN: EPILAK</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adolescent ; Age Factors ; Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Behavioral problems ; Benign rolandic epilepsy ; Biological and medical sciences ; Carbamazepine ; Carbamazepine - adverse effects ; Carbamazepine - therapeutic use ; Child ; Child Behavior Disorders - chemically induced ; Child Behavior Disorders - diagnosis ; Child Behavior Disorders - epidemiology ; Child, Preschool ; Cognition Disorders - chemically induced ; Cognition Disorders - diagnosis ; Cognition Disorders - epidemiology ; Cognitive function ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug toxicity and drugs side effects treatment ; Epilepsy, Rolandic - drug therapy ; Epilepsy, Rolandic - psychology ; Fructose - adverse effects ; Fructose - analogs & derivatives ; Fructose - therapeutic use ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; Medical sciences ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Nervous system (semeiology, syndromes) ; Neurology ; Neuropharmacology ; Neuropsychological Tests - statistics & numerical data ; Personality Inventory ; Pharmacology. Drug treatments ; Topiramate ; Treatment Outcome</subject><ispartof>Epilepsia (Copenhagen), 2007-09, Vol.48 (9), p.1716-1723</ispartof><rights>2007 International League Against Epilepsy</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3</citedby><cites>FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1528-1167.2007.01160.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1528-1167.2007.01160.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19054377$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17561952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Hoon‐Chul</creatorcontrib><creatorcontrib>Eun, Baik‐Lin</creatorcontrib><creatorcontrib>Wu Lee, Chang</creatorcontrib><creatorcontrib>Ku Moon, Han</creatorcontrib><creatorcontrib>Kim, Joon‐Sik</creatorcontrib><creatorcontrib>Wook Kim, Dong</creatorcontrib><creatorcontrib>Soo Lee, Joon</creatorcontrib><creatorcontrib>Young Chae, Kyu</creatorcontrib><creatorcontrib>Ho Cha, Byung</creatorcontrib><creatorcontrib>Sook Suh, Eun</creatorcontrib><creatorcontrib>Chae Park, Jung</creatorcontrib><creatorcontrib>Lim, Kyunghwa</creatorcontrib><creatorcontrib>Hye Ha, Eun</creatorcontrib><creatorcontrib>Ho Song, Dong</creatorcontrib><creatorcontrib>Dong Kim, Heung</creatorcontrib><creatorcontrib>Korean Pediatric Topiramate Study Group</creatorcontrib><title>The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Methods: A multicenter, randomized, open‐label, observer‐blinded, parallel‐group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment.
Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM.
Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.</description><subject>Adolescent</subject><subject>Age Factors</subject><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Behavioral problems</subject><subject>Benign rolandic epilepsy</subject><subject>Biological and medical sciences</subject><subject>Carbamazepine</subject><subject>Carbamazepine - adverse effects</subject><subject>Carbamazepine - therapeutic use</subject><subject>Child</subject><subject>Child Behavior Disorders - chemically induced</subject><subject>Child Behavior Disorders - diagnosis</subject><subject>Child Behavior Disorders - epidemiology</subject><subject>Child, Preschool</subject><subject>Cognition Disorders - chemically induced</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - epidemiology</subject><subject>Cognitive function</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epilepsy, Rolandic - drug therapy</subject><subject>Epilepsy, Rolandic - psychology</subject><subject>Fructose - adverse effects</subject><subject>Fructose - analogs & derivatives</subject><subject>Fructose - therapeutic use</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuropsychological Tests - statistics & numerical data</subject><subject>Personality Inventory</subject><subject>Pharmacology. Drug treatments</subject><subject>Topiramate</subject><subject>Treatment Outcome</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNkc1u1DAQxy0EokvhFZAvcEuwnXWcPXCAaEsrFVGh5Wx57XHjVWIHO9t2eZW-LE53Ra_44tHMbz7_CGFKSprfp11JOWsKSmtRMkJESbJJyocXaPEv8BItCKFVseINOUNvUtqRTNaieo3OqOA1XXG2QI-bDvDaWtBTwsHjNtx6N7k7wBd7ryeXXcob_BU6dedCVD2-iWHbw5BpizdhdFENaoKcOIwqgsFTwK2K2-z9A6PzgFXC34MPUwdRjQdsQ8Rt53oTweN7N3W5uHe3Hv8MfW7lNF6ProcxHd6iV1b1Cd6d_nP062K9aS-L6x_frtov14VeioYUSy3qvA3YuiFCCcG2XDDT1HlHazRTlDeam0rb2gDT1BIqrGDW2EZVZEl1dY4-HuuOMfzeQ5rk4JKGPo8DYZ8kIzyDdZXB5gjqGFKKYOUY3aDiQVIiZ2HkTs73l_P95SyMfBJGPuTU96ce--0A5jnxpEQGPpwAlbTqbVReu_TMrQhfVkJk7vORu89HOvz3AHJ9czVb1V8BDatT</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Kang, Hoon‐Chul</creator><creator>Eun, Baik‐Lin</creator><creator>Wu Lee, Chang</creator><creator>Ku Moon, Han</creator><creator>Kim, Joon‐Sik</creator><creator>Wook Kim, Dong</creator><creator>Soo Lee, Joon</creator><creator>Young Chae, Kyu</creator><creator>Ho Cha, Byung</creator><creator>Sook Suh, Eun</creator><creator>Chae Park, Jung</creator><creator>Lim, Kyunghwa</creator><creator>Hye Ha, Eun</creator><creator>Ho Song, Dong</creator><creator>Dong Kim, Heung</creator><general>Blackwell Publishing Inc</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200709</creationdate><title>The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy</title><author>Kang, Hoon‐Chul ; Eun, Baik‐Lin ; Wu Lee, Chang ; Ku Moon, Han ; Kim, Joon‐Sik ; Wook Kim, Dong ; Soo Lee, Joon ; Young Chae, Kyu ; Ho Cha, Byung ; Sook Suh, Eun ; Chae Park, Jung ; Lim, Kyunghwa ; Hye Ha, Eun ; Ho Song, Dong ; Dong Kim, Heung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Age Factors</topic><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Behavioral problems</topic><topic>Benign rolandic epilepsy</topic><topic>Biological and medical sciences</topic><topic>Carbamazepine</topic><topic>Carbamazepine - adverse effects</topic><topic>Carbamazepine - therapeutic use</topic><topic>Child</topic><topic>Child Behavior Disorders - chemically induced</topic><topic>Child Behavior Disorders - diagnosis</topic><topic>Child Behavior Disorders - epidemiology</topic><topic>Child, Preschool</topic><topic>Cognition Disorders - chemically induced</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - epidemiology</topic><topic>Cognitive function</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epilepsy, Rolandic - drug therapy</topic><topic>Epilepsy, Rolandic - psychology</topic><topic>Fructose - adverse effects</topic><topic>Fructose - analogs & derivatives</topic><topic>Fructose - therapeutic use</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuropsychological Tests - statistics & numerical data</topic><topic>Personality Inventory</topic><topic>Pharmacology. Drug treatments</topic><topic>Topiramate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Hoon‐Chul</creatorcontrib><creatorcontrib>Eun, Baik‐Lin</creatorcontrib><creatorcontrib>Wu Lee, Chang</creatorcontrib><creatorcontrib>Ku Moon, Han</creatorcontrib><creatorcontrib>Kim, Joon‐Sik</creatorcontrib><creatorcontrib>Wook Kim, Dong</creatorcontrib><creatorcontrib>Soo Lee, Joon</creatorcontrib><creatorcontrib>Young Chae, Kyu</creatorcontrib><creatorcontrib>Ho Cha, Byung</creatorcontrib><creatorcontrib>Sook Suh, Eun</creatorcontrib><creatorcontrib>Chae Park, Jung</creatorcontrib><creatorcontrib>Lim, Kyunghwa</creatorcontrib><creatorcontrib>Hye Ha, Eun</creatorcontrib><creatorcontrib>Ho Song, Dong</creatorcontrib><creatorcontrib>Dong Kim, Heung</creatorcontrib><creatorcontrib>Korean Pediatric Topiramate Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Hoon‐Chul</au><au>Eun, Baik‐Lin</au><au>Wu Lee, Chang</au><au>Ku Moon, Han</au><au>Kim, Joon‐Sik</au><au>Wook Kim, Dong</au><au>Soo Lee, Joon</au><au>Young Chae, Kyu</au><au>Ho Cha, Byung</au><au>Sook Suh, Eun</au><au>Chae Park, Jung</au><au>Lim, Kyunghwa</au><au>Hye Ha, Eun</au><au>Ho Song, Dong</au><au>Dong Kim, Heung</au><aucorp>Korean Pediatric Topiramate Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2007-09</date><risdate>2007</risdate><volume>48</volume><issue>9</issue><spage>1716</spage><epage>1723</epage><pages>1716-1723</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><coden>EPILAK</coden><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Methods: A multicenter, randomized, open‐label, observer‐blinded, parallel‐group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment.
Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM.
Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>17561952</pmid><doi>10.1111/j.1528-1167.2007.01160.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2007-09, Vol.48 (9), p.1716-1723 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20530463 |
| source | Wiley |
| subjects | Adolescent Age Factors Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Anticonvulsants. Antiepileptics. Antiparkinson agents Behavioral problems Benign rolandic epilepsy Biological and medical sciences Carbamazepine Carbamazepine - adverse effects Carbamazepine - therapeutic use Child Child Behavior Disorders - chemically induced Child Behavior Disorders - diagnosis Child Behavior Disorders - epidemiology Child, Preschool Cognition Disorders - chemically induced Cognition Disorders - diagnosis Cognition Disorders - epidemiology Cognitive function Dose-Response Relationship, Drug Drug Administration Schedule Drug toxicity and drugs side effects treatment Epilepsy, Rolandic - drug therapy Epilepsy, Rolandic - psychology Fructose - adverse effects Fructose - analogs & derivatives Fructose - therapeutic use Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Medical sciences Miscellaneous (drug allergy, mutagens, teratogens...) Nervous system (semeiology, syndromes) Neurology Neuropharmacology Neuropsychological Tests - statistics & numerical data Personality Inventory Pharmacology. Drug treatments Topiramate Treatment Outcome |
| title | The Effects on Cognitive Function and Behavioral Problems of Topiramate Compared to Carbamazepine as Monotherapy for Children with Benign Rolandic Epilepsy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20on%20Cognitive%20Function%20and%20Behavioral%20Problems%20of%20Topiramate%20Compared%20to%20Carbamazepine%20as%20Monotherapy%20for%20Children%20with%20Benign%20Rolandic%20Epilepsy&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Kang,%20Hoon%E2%80%90Chul&rft.aucorp=Korean%20Pediatric%20Topiramate%20Study%20Group&rft.date=2007-09&rft.volume=48&rft.issue=9&rft.spage=1716&rft.epage=1723&rft.pages=1716-1723&rft.issn=0013-9580&rft.eissn=1528-1167&rft.coden=EPILAK&rft_id=info:doi/10.1111/j.1528-1167.2007.01160.x&rft_dat=%3Cproquest_cross%3E20530463%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4780-4c76619ef6807a772b572d86756fdc2a158c5d3cf6de2c1f017f72fdf8a3041c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20530463&rft_id=info:pmid/17561952&rfr_iscdi=true |